MAYTANSINE

MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.

Cross Reference

Introduction

To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with MAYTANSINE?

MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with MAYTANSINE

MeSH term MeSH ID Detail
Breast Neoplasms D001943 24 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Melanoma D008545 69 associated lipids
Brain Diseases D001927 27 associated lipids
Leukemia P388 D007941 43 associated lipids
Hyperplasia D006965 34 associated lipids
Leukemia D007938 74 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Bronchial Spasm D001986 18 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Asthenia D001247 5 associated lipids
Hypopharyngeal Neoplasms D007012 1 associated lipids
Per page 10 20 | Total 17

PubChem Associated disorders and diseases

What pathways are associated with MAYTANSINE

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with MAYTANSINE?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with MAYTANSINE?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with MAYTANSINE?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with MAYTANSINE?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with MAYTANSINE?

Xenograft Model

Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with MAYTANSINE

Download all related citations
Per page 10 20 50 100 | Total 611
Authors Title Published Journal PubMed Link
Martin M et al. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. 2016 Ann. Oncol. pmid:27052654
Coiffier B et al. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. 2016 Br. J. Haematol. pmid:27010483
Frenel JS et al. [Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases]. 2016 Bull Cancer pmid:26992855
Lanshoeft C et al. Analysis of small molecule antibody-drug conjugate catabolites in rat liver and tumor tissue by liquid extraction surface analysis micro-capillary liquid chromatography/tandem mass spectrometry. 2016 Rapid Commun. Mass Spectrom. pmid:26969923
Shah MH et al. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. 2016 Invest New Drugs pmid:26961907
Dillon RL et al. Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance. 2016 J. Immunother. pmid:26938945
Kashiwaba M et al. A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. 2016 Jpn. J. Clin. Oncol. pmid:26917603
Squires H et al. Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. 2016 Pharmacoeconomics pmid:26892972
Jerjian TV et al. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy. 2016 Pharmacotherapy pmid:26799352
Venkatesan P Trastuzumab emtansine for HER2-positive breast cancer. 2016 Lancet Oncol. pmid:27866859
Nonagase Y et al. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. 2016 Oncotarget pmid:27768588
Milowsky MI et al. Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. 2016 Urol. Oncol. pmid:27765518
Walles M et al. New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats. 2016 Drug Metab. Dispos. pmid:27122302
Ogitani Y et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. 2016 Clin. Cancer Res. pmid:27026201
Baselga J et al. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. 2016 Clin. Cancer Res. pmid:26920887
Sibaud V et al. T-DM1 extravasation: first description. 2016 J Eur Acad Dermatol Venereol pmid:25879278
Force J et al. Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. 2016 J. Clin. Oncol. pmid:24778392
Catcott KC et al. Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates. 2016 MAbs pmid:26752675
Yan H et al. Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity. 2016 Mol. Cancer Ther. pmid:26712117
Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate. 2016 Cancer Discov pmid:26701087
T-DM1 Extends Survival in HER2+ Breast Cancer. 2016 Cancer Discov pmid:26676162
Askoxylakis V et al. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. 2016 J. Natl. Cancer Inst. pmid:26547932
Storz U Antibody-drug conjugates: Intellectual property considerations. 2015 MAbs pmid:26292154
Nguyen M et al. Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. 2015 Clin. Cancer Res. pmid:26240273
Chung YC et al. Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). 2015 PLoS ONE pmid:26172389
Beerli RR et al. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. 2015 PLoS ONE pmid:26132162
van Geel R et al. Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates. 2015 Bioconjug. Chem. pmid:26061183
Miranda Romero P and Marín Gil R Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report. 2015 Farm Hosp pmid:26005893
Esteva FJ et al. What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience? 2015 Am Soc Clin Oncol Educ Book pmid:25993162
Hamblett KJ et al. AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. 2015 Mol. Cancer Ther. pmid:25931519
Ab O et al. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. 2015 Mol. Cancer Ther. pmid:25904506
Weiler D et al. Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer. 2015 J Thorac Oncol pmid:25789838
Krop IE et al. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. 2015 J. Clin. Oncol. pmid:25713436
Marcoux J et al. Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. 2015 Protein Sci. pmid:25694334
Goldmacher VS et al. High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction. 2015 PLoS ONE pmid:25671541
Müller P et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. 2015 Sci Transl Med pmid:26606967
Eisenstein M Medicine: Eyes on the target. 2015 Nature pmid:26580159
Widdison WC et al. Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing. 2015 Bioconjug. Chem. pmid:26355774
Cosmai L et al. Renal toxicity of anticancer agents targeting HER2 and EGFR. 2015 J. Nephrol. pmid:26341657
Fishkin N Maytansinoid-BODIPY Conjugates: Application to Microscale Determination of Drug Extinction Coefficients and for Quantification of Maytansinoid Analytes. 2015 Mol. Pharm. pmid:25738231
Goldmacher VS et al. Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates. 2015 Mol. Pharm. pmid:25635630
Ahmed S et al. HER2-directed therapy: current treatment options for HER2-positive breast cancer. 2015 Breast Cancer pmid:25634227
Foglietta J et al. Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'. 2015 Ann. Oncol. pmid:25632067
Wiggins B et al. Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates. 2015 J Pharm Sci pmid:25631158
Lai KC et al. Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay. 2015 Pharm. Res. pmid:25630819
Li T et al. Improvement of ansamitocin P-3 production by Actinosynnema mirum with fructose as the sole carbon source. 2015 Appl. Biochem. Biotechnol. pmid:25564203
Carneiro BA et al. Emerging therapeutic targets in bladder cancer. 2015 Cancer Treat. Rev. pmid:25498841
Mang Y et al. Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent mice. 2015 Int. Immunopharmacol. pmid:25467246
Kalsi R et al. Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. 2015 Clin. Breast Cancer pmid:25454740
Sibaud V et al. T-DM1-related telangiectasias: a potential role in secondary bleeding events. 2015 Ann. Oncol. pmid:25403586